Abstract library

573 results for "Bowel Cancer Screening".
#1459 Does Faecal Occult Blood Testing Help Identify Ileo-Colonic NETs in the UK Bowel Cancer Screening Programme (BCSP)?
Introduction: There has been an increase in the incidence of ileo-colonic NETs in recent years, partly from endoscopy. There is no published data on the incidence of NETs diagnosed in the UK ‘double’ screen BCSP of initial Faecal Occult Blood stool test (FOBt) and, if abnormal, colonoscopy. The incidence (per 100k) of colorectal cancer (CRC) in FOBt abnormal UK BCSP colonoscopy is 55 times that of the population incidence (10k vs 184).
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Ron Basuroy
#1585 Incidence and Characteristics of Ileo-colonic Neuroendocrine Tumours Identified in the UK Bowel Cancer Screening Programme
Introduction: Colorectal cancer is the third most common cancer in the UK this had led to development of the bowel cancer screening programmes (BCSPs).There are few epidemiological data on rectal or ileal NETs diagnosed in BCSPs.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Raj Srirajaskanthan
Keywords: screening
#306 The Risk of Metachronous Cancers In Patients with Small Intestinal Carcinoid Tumors
Introduction: Small intestinal carcinoids (SIC) are the most common small bowel malignancies. No population-based study has examined the risk for, and prognosis of, metachronous cancers and SICs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Michelle Kim
Authors: Amin S, Warner R R, Itzkowitz S, Kim M, ...
#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#1819 Initial Experience of a Novel Endoscopic Full Thickness Resection Device (FTRD) for the Treatment of Rectal Neuroendocrine Tumours
Introduction: Standard endoscopic resection of rectal NETs is often associated with histological incomplete excision due to submucosal position within the bowel. Endoscopic full thickness resection may allow early definitive management.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: John Knight
Authors: Fong M, Ramsey E, Boger P, Ellis R, ...
#2301 Trends in Management of Gastro-Intestinal Neuroendocrine Tumors in Inflammatory Bowel Diseases: The Contribute of a Case Series.
Introduction: The risk to develop gastro-intestinal malignancies is higher in patients affected by inflammatory bowel diseases (IBD). Apart from colo-rectal cancer, related to a long standing inflammation, there is a growing evidence of neuroendocrine tumors (NETs) in these patients and a correlation between these two diseases has been postulated. We report four cases of NETs in IBD.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Doctor Stefano Rizza
#864 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Medullary Thyroid Cancer: A Retrospective Cohort Study
Introduction: Hereditary Medullary Thyroid Cancer (MTC) accounts for 20-30% of cases and has some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Valeria Ramundo
#1704 Diffusion Weighted Imaging as a Screening Tool in the Detection and Monitoring of Pancreatic Neuroendocrine Tumours in Patients with Familial Cancer Syndromes.
Introduction: Pancreatic neuroendocrine tumours (PNETs) occur at a higher frequency and at a younger age in patients with certain genetic conditions e.g. Von Hippel Lindau and Multiple Endocrine Neoplasia type 1. Screening for early detection and monitoring growth rates of PNETs in these high risk patients is vital in their management. MRI has emerged as the gold standard for imaging the pancreas for the detection of PNETs and diffusion weighted imaging (DWI) has become an invaluable adjunct.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Carys Jenkins
Authors: Jenkins C, Thomas W, Parry C, Khan M, ...
Keywords: PNET, MRI, VHL, MEN1
#1443 Second Primary Malignancies Incidence in Patients with Neuroendocrine Tumours – Retrospective Review of 454 Neuroendocrine Tumour Cases
Introduction: Increased incidence of second primary malignancies (SPM) in patients (pts) with neuroendocrine tumors (NET) has been reported.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj